Videos

The expert faculty discuss practical and logistical considerations for integrating novel immunotherapies into clinical management of high-risk non–muscle-invasive bladder cancer (NMIBC).

John Michael DiBianco, MD, discusses the design of the ongoing SOUL trial, which is assessing stent omission vs stent placement following uncomplicated ureteroscopy.

Ilaha Isali, MD, MSc, identifies major unresolved gaps in sex-specific bladder cancer research.

Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions.

Dean Elterman, MD, MSc, FRCSC, attributes the 99% catheter-free discharge rate in the BREEZE study largely to appropriate patient selection.

Steven A. Kaplan, MD, frames the greatest value of ProVee not as competition with other procedures, but as a compelling alternative to chronic medical therapy.

Steven A. Kaplan, MD, emphasizes that ProVee is well suited for office-based or ambulatory settings and is designed to be performed under local anesthesia

Exogenous testosterone therapy and fertility are fundamentally incompatible.

Although the trial includes multiple tumor types, the presented data focus on RCC, predominantly clear cell disease.

Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year.

Experts discuss the importance and limitations of real-world evidence in assessing cardiovascular risks associated with ARPIs, emphasizing the need for critical analysis.

Experts discuss the importance of managing cardiovascular health and bone health in prostate cancer treatment, emphasizing real-world data and patient care strategies.

Regarding compounded testosterone products, Jesse N. Mills, MD, takes a balanced but cautious stance.

The review highlights the role of sex chromosome biology, particularly genes on the X chromosome that escape inactivation.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Discover the critical timing and stability considerations for rectal spacers in radiation therapy, ensuring optimal patient outcomes and treatment precision.

Healthcare professionals discuss the importance of patient counseling on treatment options, emphasizing the balance between efficacy and quality of life.

Dean Elterman, MD, MSc, FRCSC, emphasizes that a key differentiator of this new class of devices lies in material science and mechanism of action.

Explore advancements in prostate cancer treatment, focusing on the role of rectal spacers in enhancing radiation therapy safety and effectiveness.

Hormonal changes influence fluid balance and bloating, increasing pressure within the pelvis.

Maxwell L. Sandberg, MD, highlights recent study findings on the role for perioperative systemic therapy for renal cell carcinoma with a tumor thrombus.

The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive implications for non–muscle-invasive bladder cancer (NMIBC).

Mechanistically, Kaplan emphasizes that ProVee’s key differentiator is not simply that it is an expanding urethral device, but that it belongs to a new class of flexible, catheter-like technologies.

Raveen Syan, MD, FPMRS, shares her excitement about the Rising Star Program, now entering its second year.

The expert faculty explore how to select appropriate patients for future use of systemic immunotherapy combined with BCG in high-risk non–muscle invasive bladder cancer (NMIBC), assuming approval of durvalumab or sasanlimab.

Madison Krischak, MD, outlines key findings from a study looking at the use of nephrometry scores to guide routine renal mass biopsies.

Beyond the new features, attendees can expect a focused, high-yield scientific program covering both benign and oncologic disease.

The SOUL trial is exploring the feasibility of stent omission following uncomplicated ureteroscopy.

Overall, germline pathogenic variants were common, identified in approximately 1 in 7 tested patients.